U.S. Department of Health and Human Services Awards Kaléo with Contract to Develop Next Generation Organophosphate Nerve Agent Poisoning Countermeasure Richmond, Virginia, April 17, 2024 (GLOBE NEWSWIRE) -- Kaléo, a privately-held U.S. pharmaceutical company today announced their selection by the Biomedical Advanced Research and Development...